These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 22538522)

  • 81. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis.
    Mathieu S; Couderc M; Pereira B; Soubrier M
    Semin Arthritis Rheum; 2013 Dec; 43(3):e1-2. PubMed ID: 23810615
    [No Abstract]   [Full Text] [Related]  

  • 82. Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
    Strand V
    Z Rheumatol; 1998 Feb; 57(1):41-5. PubMed ID: 9566107
    [No Abstract]   [Full Text] [Related]  

  • 83. [Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].
    Imai E
    Nihon Jinzo Gakkai Shi; 2012; 54(5):593-7. PubMed ID: 22991838
    [No Abstract]   [Full Text] [Related]  

  • 84. Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs.
    Diamantopoulos AP; Haugeberg G
    Mod Rheumatol; 2012 Apr; 22(2):295-7. PubMed ID: 21706387
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Advances in targeted therapy: safety of biological agents.
    Keystone EC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii34-6. PubMed ID: 14532146
    [No Abstract]   [Full Text] [Related]  

  • 86. Extensive and severe CNS demyelination associated with golimumab therapy.
    Maillart E; Papeix C; Mellerio C; Bertrand A; Lubetzki C; Louapre C
    J Neurol; 2016 Sep; 263(9):1869-71. PubMed ID: 27456211
    [No Abstract]   [Full Text] [Related]  

  • 87. Effect of combination of anticytokine preparations anaferon and artrofoon on immune inflammation in rheumatoid arthritis.
    Petrov VI; Babaeva AR; Solodenkova KS; Cherevkova EV; Zabolotneva YA; Kachanova MV; Sergeeva SA
    Bull Exp Biol Med; 2009 Sep; 148(3):489-92. PubMed ID: 20396720
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Rheumatoid arthritis and the era of biologic therapy.
    Malaviya AP; Ostör AJ
    Inflammopharmacology; 2012 Apr; 20(2):59-69. PubMed ID: 22366810
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 90. Five-year data from the REFLEX study: a different interpretation.
    Abeles AM
    J Rheumatol; 2013 May; 40(5):732. PubMed ID: 23637377
    [No Abstract]   [Full Text] [Related]  

  • 91. Summaries for patients. What is the best treatment plan for early rheumatoid arthritis?
    Ann Intern Med; 2007 Mar; 146(6):I63. PubMed ID: 17371882
    [No Abstract]   [Full Text] [Related]  

  • 92. Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment: comments on the article by Smale and Lawson.
    Mielnik P; Hjelle AM; Szatkowski D
    Scand J Rheumatol; 2013; 42(4):335-6. PubMed ID: 23829547
    [No Abstract]   [Full Text] [Related]  

  • 93. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.
    Solomon DH; Mercer E; Kavanaugh A
    Arthritis Rheum; 2012 Jan; 64(1):21-32. PubMed ID: 21898354
    [No Abstract]   [Full Text] [Related]  

  • 94. Dr. Keystone, et al, reply.
    J Rheumatol; 2013 May; 40(5):732-3. PubMed ID: 23767071
    [No Abstract]   [Full Text] [Related]  

  • 95. Longterm treatment benefits are best reflected by patient reported outcomes.
    Strand CV; Crawford B
    J Rheumatol; 2007 Dec; 34(12):2317-9. PubMed ID: 18061963
    [No Abstract]   [Full Text] [Related]  

  • 96. FDA approves tocilizumab to treat rheumatoid arthritis.
    Thompson CA
    Am J Health Syst Pharm; 2010 Feb; 67(4):254. PubMed ID: 20133526
    [No Abstract]   [Full Text] [Related]  

  • 97. [Position on choice of agents among TNF inhibitors].
    Manger B;
    Z Rheumatol; 2005 Mar; 64(2):88-9. PubMed ID: 15793672
    [No Abstract]   [Full Text] [Related]  

  • 98. Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al.
    Yazici H; Yazici Y
    Arthritis Rheum; 2012 Jul; 64(7):2414; author reply 2414-5. PubMed ID: 22549846
    [No Abstract]   [Full Text] [Related]  

  • 99. [The multidisciplinary practice guideline "The responsible use of biologicals"].
    Bijlsma JW; Hagemeijer JW; Bijl M; Jansen TL; van de Laar MA; Landewé RB; Nurmohamed MT
    Ned Tijdschr Geneeskd; 2011; 155(30-31):A3114. PubMed ID: 22085508
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Therapy: what should we do after the failure of a first anti-TNF?
    Deighton C
    Nat Rev Rheumatol; 2009 Nov; 5(11):596-7. PubMed ID: 19865088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.